Caribou Biosciences (CRBU) Cash from Investing Activities (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Cash from Investing Activities data on file, last reported at $24.0 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $24.0 million, down 51.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $76.8 million (down 32.02% YoY), and the FY2025 annual result was $102.2 million, up 18.05% from the prior year.
• Cash from Investing Activities climbed to $24.0 million in Q1 2026 per CRBU's latest filing, from $18.0 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $49.4 million in Q1 2025 and troughed at -$72.1 million in Q1 2022.
• A 5-year average of $3.0 million and a median of $15.9 million in 2024 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities sank 327659.09% in 2022, then jumped 179.18% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at $1.2 million in 2022, then slumped by 2790.09% to -$31.5 million in 2023, then jumped by 150.61% to $15.9 million in 2024, then grew by 12.81% to $18.0 million in 2025, then surged by 33.47% to $24.0 million in 2026.
• Business Quant data shows CRBU's Cash from Investing Activities at $24.0 million in Q1 2026, $18.0 million in Q4 2025, and $10.9 million in Q3 2025.